Switch theme
Sign up to access all valuation multiples
Circio Holding ASA is a clinical-stage company. It is focused on developing and commercializing immuno-oncology therapies to target treatment-resistant solid tumors. Its product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to infect cancer cells and activate the immune system to fight cancer. It includes the development and implementation with the purpose of developing targeted immunotherapy treatments for cancer patients. The company's pipeline candidate includes circVec and Mutant KRAS.
2010
10
LTM Revenue $4.0M
LTM EBITDA -$1.9M
$5.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Circio Holding has a last 12-month revenue (LTM) of $4.0M and a last 12-month EBITDA of -$1.9M.
In the most recent fiscal year, Circio Holding achieved revenue of n/a and an EBITDA of $5.6M.
Circio Holding expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Circio Holding valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $4.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$1.9M | XXX | $5.6M | XXX | XXX | XXX |
| EBITDA Margin | -47% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$1.9M | XXX | -$4.2M | XXX | XXX | XXX |
| EBIT Margin | -47% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | $1.8M | XXX | $5.6M | XXX | XXX | XXX |
| Net Margin | 44% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Circio Holding's stock price is NOK 1 (or $0).
Circio Holding has current market cap of NOK 60.5M (or $5.9M), and EV of NOK 59.7M (or $5.8M).
See Circio Holding trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.8M | $5.9M | XXX | XXX | XXX | XXX | $0.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Circio Holding has market cap of $5.9M and EV of $5.8M.
Circio Holding's trades at 485.2x EV/Revenue multiple, and 1.0x EV/EBITDA.
Equity research analysts estimate Circio Holding's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Circio Holding has a P/E ratio of 3.4x.
See valuation multiples for Circio Holding and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.9M | XXX | $5.9M | XXX | XXX | XXX |
| EV (current) | $5.8M | XXX | $5.8M | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | 485.2x | XXX | XXX | XXX |
| EV/EBITDA | -3.1x | XXX | 1.0x | XXX | XXX | XXX |
| EV/EBIT | -3.1x | XXX | -1.4x | XXX | XXX | XXX |
| EV/Gross Profit | 1.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 3.4x | XXX | 1.1x | XXX | XXX | XXX |
| EV/FCF | 3.4x | XXX | -1.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCircio Holding's last 12 month revenue growth is 142%
Circio Holding's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.4M for the same period.
Circio Holding's rule of 40 is -85554% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Circio Holding's rule of X is 308% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Circio Holding and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 142% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -47% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -204% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -85554% | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 308% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Circio Holding acquired XXX companies to date.
Last acquisition by Circio Holding was XXXXXXXX, XXXXX XXXXX XXXXXX . Circio Holding acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Circio Holding founded? | Circio Holding was founded in 2010. |
| Where is Circio Holding headquartered? | Circio Holding is headquartered in Norway. |
| How many employees does Circio Holding have? | As of today, Circio Holding has 10 employees. |
| Is Circio Holding publicy listed? | Yes, Circio Holding is a public company listed on OSL. |
| What is the stock symbol of Circio Holding? | Circio Holding trades under CRNA ticker. |
| When did Circio Holding go public? | Circio Holding went public in 2016. |
| Who are competitors of Circio Holding? | Similar companies to Circio Holding include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Circio Holding? | Circio Holding's current market cap is $5.9M |
| What is the current revenue of Circio Holding? | Circio Holding's last 12 months revenue is $4.0M. |
| What is the current revenue growth of Circio Holding? | Circio Holding revenue growth (NTM/LTM) is 142%. |
| What is the current EV/Revenue multiple of Circio Holding? | Current revenue multiple of Circio Holding is 1.4x. |
| Is Circio Holding profitable? | Yes, Circio Holding is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Circio Holding? | Circio Holding's last 12 months EBITDA is -$1.9M. |
| What is Circio Holding's EBITDA margin? | Circio Holding's last 12 months EBITDA margin is -47%. |
| What is the current EV/EBITDA multiple of Circio Holding? | Current EBITDA multiple of Circio Holding is -3.1x. |
| What is the current FCF of Circio Holding? | Circio Holding's last 12 months FCF is $1.7M. |
| What is Circio Holding's FCF margin? | Circio Holding's last 12 months FCF margin is 42%. |
| What is the current EV/FCF multiple of Circio Holding? | Current FCF multiple of Circio Holding is 3.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
